In ONWARDS 6 [62], the only phase 3 trial regarding the use of once-weekly insulin icodec vs. once-daily insulin degludec in combination with insulin aspart in people with T1DM, insulin icodec was non-inferior to insulin degludec in terms of HbA1c reduction, but severe hypoglycemia episodes occurred in the insulin icodec group. This evidence concerns the gene INS and Hypoglycemia.